MINIMAL RESIDUAL DISEASE (MRD) MONITORING FOR B-CLL
Rs 15,840 Rs 12,000
24 % OFF
THIS ASSAY HELPS TO ASSESS RESPONSE TO THERAPY AND COMPARES THE EFFICACY OF DIFFERENT THERAPEUTIC APPROACHES. DETECTION OF MINIMAL RESIDUAL DISEASE LEVEL PREDICTS PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL AFTER ROUTINE CHEMOTHERAPY, AFTER IMMUNOCHEMOTHERAPY AND AFTER STEM CELL TRANSPLANTATION. THE ERADICATION OF MINIMAL RESIDUAL DISEASE IN CLL PREDICTS FOR IMPROVED OUTCOME.
Why book with us?
-
Free and On Schedule Sample Collection
-
24/7 Service
-
Affordable
-
Quick and Accurate Reports
3 ML (1 ML MIN.) BONE MARROW (FIRST PULL ASPIRATE) IN 1 GREEN TOP (SODIUM HEPARIN) TUBE AND 4 ML (3 ML MIN.) WHOLE BLOOD IN 2 GREEN TOP (SODIUM HEPARIN) TUBES. MIX THOROUGHLY & SHIP IMMEDIATELY AT 18 22 C OR 2-8 DEG C. DO NOT FREEZE. FOLLOWING INFORMATION IS MANDATORY: SAMPLE TIME POINT (CHEMOTHERAPY TIME POINTS); PREVIOUS DIAGNOSTIC IMMUNOPHENOTYPE REPORT; CLINICAL HISTORY AND ORIGINAL TRF; DATE AND TIME WHEN SAMPLE WAS DRAWN TO BE MENTIONED ON THE TRF; THERAPY DETAILS; 2 OR 3 UNSTAINED BMA SMEARS OR PERIPHERAL SMEARS TO BE MADE AT SOURCE.
FLOW CYTOMETRY
REPORT ON 4TH DAY EVENING 7PM
FOLLOWING INFORMATION IS MANDATORY: SAMPLE TIME POINT (CHEMOTHERAPY TIME POINTS); PREVIOUS DIAGNOSTIC IMMUNOPHENOTYPE REPORT; CLINICAL HISTORY AND ORIGINAL TRF; DATE AND TIME WHEN SAMPLE WAS DRAWN TO BE MENTIONED ON THE TRF; THERAPY DETAILS.
